Zenas BioPharma, Inc. (ZBIO)
29.67
+1.41
(+4.99%)
USD |
NASDAQ |
Nov 09, 14:54
Zenas BioPharma Enterprise Value : 1.731B for Nov. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 06, 2026 | 1.731B |
| November 05, 2026 | 1.573B |
| November 04, 2026 | 1.744B |
| November 03, 2026 | 1.739B |
| November 02, 2026 | 1.687B |
| October 30, 2026 | 1.739B |
| October 29, 2026 | 1.765B |
| October 28, 2026 | 1.765B |
| October 27, 2026 | 1.666B |
| October 26, 2026 | 1.662B |
| October 23, 2026 | 1.636B |
| October 22, 2026 | 1.729B |
| October 21, 2026 | 1.718B |
| October 20, 2026 | 1.725B |
| October 19, 2026 | 1.626B |
| October 16, 2026 | 1.499B |
| October 15, 2026 | 1.537B |
| October 14, 2026 | 1.500B |
| October 13, 2026 | 1.520B |
| October 12, 2026 | 1.605B |
| October 09, 2026 | 1.663B |
| October 08, 2026 | 1.594B |
| October 07, 2026 | 1.725B |
| October 06, 2026 | 1.641B |
| October 05, 2026 | 1.702B |
| Date | Value |
|---|---|
| October 02, 2026 | 1.733B |
| October 01, 2026 | 1.709B |
| September 30, 2026 | 1.643B |
| September 29, 2026 | 1.441B |
| September 28, 2026 | 1.491B |
| September 25, 2026 | 1.453B |
| September 24, 2026 | 1.488B |
| September 23, 2026 | 1.623B |
| September 22, 2026 | 1.840B |
| September 21, 2026 | 1.808B |
| September 18, 2026 | 1.741B |
| September 17, 2026 | 1.771B |
| September 16, 2026 | 1.793B |
| September 15, 2026 | 1.769B |
| September 14, 2026 | 1.767B |
| September 11, 2026 | 1.717B |
| September 10, 2026 | 1.716B |
| September 09, 2026 | 1.791B |
| September 08, 2026 | 1.840B |
| September 04, 2026 | 1.829B |
| September 03, 2026 | 1.831B |
| September 02, 2026 | 1.845B |
| September 01, 2026 | 1.772B |
| August 31, 2026 | 1.793B |
| August 28, 2026 | 1.727B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.764B |
| Alnylam Pharmaceuticals, Inc. | 20.29B |
| Anika Therapeutics, Inc. | 176.07M |
| Savara, Inc. | 849.45M |
| Vericel Corp. | 2.710B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -108.92M |
| Revenue (Quarterly) | 10.00M |
| Total Expenses (Quarterly) | 118.92M |
| EPS Diluted (Quarterly) | -1.647 |
| Gross Profit Margin (Quarterly) | 99.96% |
| Profit Margin (Quarterly) | -1.09K% |
| Earnings Yield | -33.84% |
| Normalized Earnings Yield | -23.28 |